Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide
Jiao-Yu Zhao, Si‐Ning Liu, Lan‐Ping Xu, Xiaohui Zhang, Yu Wang, Yu‐Hong Chen, Kai‐Yan Liu, Xiao‐Jun Huang, Xiao‐Dong Mo
Topics & Concepts
RuxolitinibMedicineHematopoietic stem cell transplantationInternal medicineGraft-versus-host diseaseTransplantationHematologyCyclophosphamideSalvage therapyStem cellImmunologyGastroenterologyOncologyChemotherapyBone marrowBiologyMyelofibrosisGeneticsHematopoietic Stem Cell TransplantationT-cell and B-cell ImmunologyRenal Transplantation Outcomes and Treatments